<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Draft Guidance for Industry on Endocrine Disruption Potential of Drugs: Nonclinical Evaluation; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Draft Guidance for Industry on Endocrine Disruption Potential of Drugs: Nonclinical Evaluation; Availability</h1>
    <p class="timestamp">Published: 2013-09-20 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Endocrine Disruption Potential of Drugs: Nonclinical Evaluation." This draft guidance provides recommendations to sponsors on the parameters that should be routinely assessed in toxicology studies for investigational new drug applications (INDs), new drug applications (NDAs), and biologics license applications (BLAs) regulated by the Center for Drug Evaluation and Research to determin...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2013-22864</p>
    <p><strong>Publication Date:</strong> 2013-09-20</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2013/09/20/2013-22864/draft-guidance-for-industry-on-endocrine-disruption-potential-of-drugs-nonclinical-evaluation">https://www.federalregister.gov/documents/2013/09/20/2013-22864/draft-guidance-for-industry-on-endocrine-disruption-potential-of-drugs-nonclinical-evaluation</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2013-22864</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
